Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
expression is regulated by testosterone [RGD, Feb 2006].. De plus, nous expédions SCGB2A1 Anticorps (56) et SCGB2A1 Protéines (5) et beaucoup plus de produits pour cette protéine.
Showing 2 out of 6 products:
novel marker GATA3 (Montrer GATA3 Kits ELISA) stains a significantly higher proportion of both primary and metastatic breast carcinomas than GCDFP15 (Montrer PIP Kits ELISA) or mammaglobin with stronger and more diffuse staining, helpful in cases with small tissue samples
The commonly used breast carcinoma biomarkers vary in their prognostic implications. GCDFP-15 (Montrer PIP Kits ELISA) independently indicated a favourable prognosis. GATA-3 (Montrer GATA3 Kits ELISA) and MGB were not associated with outcome.
Results indicate that the quantitative analysis of h-MAM (Montrer ATF7IP Kits ELISA) mRNA is a useful tool for detecting CTCs in breast cancer patients.
Results indicated that SCGB2A1 represented a novel, prognostic factor for colorectal cancer, and its expression correlated with chemoresistance, radioresistance and cancer cell stemness.
The data indicate that MGB1, MGB2 and LIPB mRNAs are expressed at low levels in human tissues but basal expression is upregulated in ovarian cancer.
SCGB2A1 is a top differentially expressed gene in all major histological types of ovarian cancers.
MGB has the highest expression in HER2 (Montrer ERBB2 Kits ELISA)-overexpressing breast cancers and may be a potentially useful marker for this subtype.
Data show that plasma mammaglobin mRNA alone or in combination with CA15.3 (CD227 (Montrer MUC1 Kits ELISA)) may be used as a valuable noninvasive approach for the diagnosis and the detection of metastasis in breast cancer at the time of diagnosis.
The mammaglobin/lipophilin B (Montrer SCGB1D2 Kits ELISA) complex is a promising diagnostic marker for breast cancer.
MGB2 markers may be useful for identifying micrometastases in sentinel lymph nodes of breast cancer patients.
expression is regulated by testosterone
secretoglobin, family 2A, member 1
, lipophilin C
, mammaglobin 2
, mammaglobin B
, androgen receptor DNA-binding domain DNA
, prostatic steroid binding protein 1
, prostatic steroid binding protein, allele C3(2)
, prostatic steroid-binding protein 1
, prostatic steroid-binding protein C3.2
, secretoglobin family 2A member 1